If Abbott Laboratories had succeeded last year in its attempted acquisition of Alza Corp., it would have added a strong presence in the drug delivery and urology markets. But that effort failed after ABT and AZA (Mountain View, Calif.) failed to reach a deal with the U.S. Federal Trade Commission. Now, nearly a year after the demise of the AZA deal, ABT has opted for a very different course with its proposed $6.9 billion cash purchase of the pharmaceutical division